MoonLake Immunotherapeutics

Historical price data

MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.

Nanobody® platform: proprietary technology for developing small, stable, single-domain antibody fragments that enable superior tissue penetration and can be engineered into multivalent constructs for enhanced potency against inflammatory targets.